SANTA BARBARA, Calif.--(BUSINESS WIRE)--July 8, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), announced today that its board of directors has accepted the resignation of Gary S. Kledzik, Ph.D., as chief executive officer (CEO), chairman and director. The Company’s board of directors named director Robert J. Sutcliffe as Miravant’s new, non-executive chairman, and announced the appointment of an interim executive committee consisting of Robert J. Sutcliffe and director Rani Aliahmad to coordinate management functions, identify CEO candidates and recommend initiatives to increase productivity and leverage Miravant’s development programs. Miravant President David Mai and CFO John Philpott will report to the interim executive committee. Mr. Sutcliffe is a venture lawyer and business advisor based in Los Angeles, where he is managing director of Craftsman Capital Advisors LLC. Mr. Aliahmad serves as president of USA Call, a provider of end-to-end mobile solutions and services for the marketing arena. He has held several posts, including co-founder and COO of Cardionomics and co-founder of Embryonix.
